United States · FDA National Drug Code directory

Ondansetron

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
71335-2974_9ffcf3b8-959a-41c9-b9df-f96ea5311b44
Product NDC
71335-2974
Form
TABLET, ORALLY DISINTEGRATING
Composition / generic term
Ondansetron
Labeler
Bryant Ranch Prepack
Marketing category
ANDA
Marketing start / end (source format)
20250619
Source listing expiry
20271231

Source-listed ingredients

  • ONDANSETRON — 8 mg/1

These values do not establish equivalence or a dose recommendation.

Packages

  • 14 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2974-0) · 71335-2974-0
  • 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2974-1) · 71335-2974-1
  • 10 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2974-2) · 71335-2974-2
  • 9 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2974-3) · 71335-2974-3
  • 5 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2974-4) · 71335-2974-4
  • 3 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2974-5) · 71335-2974-5
  • 6 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2974-6) · 71335-2974-6
  • 12 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2974-7) · 71335-2974-7
  • 4 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2974-8) · 71335-2974-8
  • 20 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2974-9) · 71335-2974-9

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →